2021
Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study
Butala NM, Faridi KF, Tamez H, Strom JB, Song Y, Shen C, Secemsky EA, Mauri L, Kereiakes DJ, Curtis JP, Gibson CM, Yeh RW. Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. Circulation 2021, 145: 97-106. PMID: 34743530, PMCID: PMC8748407, DOI: 10.1161/circulationaha.121.056878.Peer-Reviewed Original ResearchConceptsContemporary clinical practiceStent-treated patientsPercutaneous coronary interventionDAPT studyProlonged DAPTClinical practiceCoronary interventionMyocardial infarctionNational Cardiovascular Data Registry CathPCI RegistryTreatment effectsTrial resultsAttenuation of benefitLonger-duration DAPTMonths of DAPTProlonged DAPT durationDrug-eluting stentsCoronary stent proceduresModern clinical practiceGreater bleedingMore comorbiditiesRegistry patientsAntiplatelet therapyCerebrovascular eventsDAPT durationMore contemporary cohortsComparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study
Faridi KF, Tamez H, Butala NM, Song Y, Shen C, Secemsky EA, Mauri L, Curtis JP, Strom JB, Yeh RW. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation Cardiovascular Quality And Outcomes 2021, 14: e006589. PMID: 33435731, PMCID: PMC7855905, DOI: 10.1161/circoutcomes.120.006589.Peer-Reviewed Original ResearchConceptsNegative predictive valuePositive predictive valueMyocardial infarctionPredictive valueDAPT studyClinical trialsAdjudicated eventsClaims dataNational Cardiovascular Data Registry CathPCI RegistryClinical events committeeTrial of patientsPercutaneous coronary interventionTrial end pointsKappa statisticsAdjudicated deathCathPCI RegistryCerebrovascular eventsCoronary interventionCumulative incidenceEvents committeeOutcome ascertainmentBilling claimsInpatient hospitalizationBleeding rateCardiovascular disease
2019
Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement
Strom JB, Zhao Y, Faridi KF, Tamez H, Butala NM, Valsdottir LR, Curtis J, Brennan JM, Shen C, Boulware M, Popma JJ, Yeh RW. Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement. Circulation Cardiovascular Interventions 2019, 12: e008231. PMID: 31694411, PMCID: PMC7212938, DOI: 10.1161/circinterventions.119.008231.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overAortic ValveAortic Valve StenosisBrain IschemiaClinical Trials as TopicDatabases, FactualFemaleHeart Valve Prosthesis ImplantationHumansIschemic Attack, TransientMaleMedicareRisk AssessmentRisk FactorsStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsNegative predictive valueAortic valve replacementCerebrovascular eventsInternational ClassificationPositive predictive valuePredictive valueValve replacementNinth RevisionClinical trialsTenth RevisionBilling codesKaplan-Meier estimatesMedicare inpatient claimsSURTAVI trialClinical event adjudicationDevastating complicationIschemic strokeNeurological eventsCerebrovascular diseaseBilling claimsInpatient claimsEvent adjudicationAdministrative claimsHigh riskTrial participants
2014
In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention
Bagai A, Wang Y, Wang TY, Curtis JP, Gurm HS, Shah B, Cheema AN, Peterson ED, Saucedo JF, Granger CB, Roe MT, Bhatt DL, McNamara RL, Alexander KP. In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. Circulation Cardiovascular Interventions 2014, 7: 585-593. PMID: 25097196, DOI: 10.1161/circinterventions.114.001555.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAge FactorsAgedClopidogrelDrug SubstitutionFemaleHumansMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPiperazinesPostoperative ComplicationsPractice Guidelines as TopicPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsRecurrenceRegistriesRisk FactorsThiophenesThrombosisTiclopidineUnited StatesConceptsPercutaneous coronary interventionMyocardial infarctionCoronary interventionHospital coronary artery bypassIntervention Outcomes Network RegistryStudy periodAcute Coronary TreatmentHierarchical logistic regression modelingCoronary artery bypassRecurrent ischemic eventsHours of admissionPrevious cerebrovascular eventsRandomized clinical trialsAcute myocardial infarctionADP receptor inhibitorsLogistic regression modelingPrivate health insurance coverageHealth insurance coverageHospital bleedingHospital switchingAngiographic characteristicsArtery bypassCerebrovascular eventsContemporary US practiceCoronary Treatment
2004
Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke
Sokol SI, Portnay EL, Curtis JP, Nelson MA, Hebert PR, Setaro JF, Foody JM. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004, 63: 208-213. PMID: 15277610, DOI: 10.1212/01.wnl.0000130360.21618.d0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin-Converting Enzyme InhibitorsAnimalsBrainChronic DiseaseDouble-Blind MethodDrug Evaluation, PreclinicalEndothelium, VascularFibrinolysisHemostasisHumansInflammationMiddle AgedNerve RegenerationRandomized Controlled Trials as TopicRatsReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Renin-Angiotensin SystemSecondary PreventionStrokeTreatment OutcomeConceptsRenin angiotensin aldosterone systemRAAS modulationRecurrent strokeAldosterone systemCerebrovascular eventsStroke preventionSecondary preventionACE inhibitorsCerebrovascular diseaseAngiotensin II type 1 receptor blocker therapiesBlood pressure-independent mechanismsMajor public health concernReceptor blocker therapyRecurrent cerebrovascular eventsRecurrent stroke preventionAngiotensin aldosterone systemBlood pressure reductionSecondary stroke preventionRecurrent cardiac eventsPressure-independent mechanismsVascular structural changesOngoing clinical trialsNew treatment strategiesPublic health concernBlocker therapy